-
1
Therapeutic effect of dihydroartemisinin on Alzheimer’s disease model mice with senile macular degeneration
Published 2025-02-01Subjects: Get full text
Article -
2
Modeling pegcetacoplan treatment effect for atrophic age-related macular degeneration with AI-based progression prediction
Published 2025-02-01Subjects: “…Age-related macular degeneration…”
Get full text
Article -
3
A cross-tissue transcriptome-wide association study identified susceptibility genes for age-related macular degeneration
Published 2025-02-01Subjects: Get full text
Article -
4
Abca4, mutated in Stargardt disease, is required for structural integrity of cone outer segments
Published 2025-01-01Subjects: Get full text
Article -
5
-
6
Predictive value of different baseline optical coherence tomography biomarkers for visual acuity changes in neovascular age-related macular degeneration
Published 2025-02-01Subjects: “…Age-related macular degeneration…”
Get full text
Article -
7
Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database
Published 2014-07-01“…**Purpose:** To identify outpatient treatment patterns of patients with exudative age-related macular degeneration (AMD) who received approved anti–vascular endothelial growth factor (VEGF) therapy, using real-world data from hospitals in Japan. …”
Get full text
Article -
8
Dry eye disease treatment improves subjective quality-of-life responses in patients with AMD, independent of disease stage.
Published 2025-01-01“…<h4>Purpose</h4>To determine the impact of severity of age-related macular degeneration (AMD) on subjective treatment response in patients treated for dry eye disease.…”
Get full text
Article -
9
Global, regional, and national burden of blindness and vision loss attributable to smoking from 1990 to 2021, and forecasts to 2030: findings from the Global Burden of Disease Stud...
Published 2025-02-01“…Methods We extracted data on years lived with disability (YLDs) and age-standardized YLDs rate (ASYR) related to blindness and vision loss (BVL) caused by smoking, including cataracts and age-related macular degeneration (AMD), from the Global Burden of Disease (GBD) database for the years 1990 to 2021. …”
Get full text
Article -
10
Association of arterial stiffness and eye disease: a systematic review and meta-analysis
Published 2025-01-01“…Background This systematic review and meta-analysis assesses the association of arterial stiffness with age-related macular degeneration (AMD), glaucoma, retinal vein occlusion (RVO) and retinopathy (diabetic and hypertensive).Methods Medline and Embase were systematically searched for observational studies of arterial stiffness and eye disease. …”
Get full text
Article -
11
Repeated exposure to low doses of light induces retinal damage in vivo in a wavelength-dependent manner
Published 2025-01-01“…However, meta-analyses pointed out the role of lifelong light exposure in the onset of age-related macular degeneration, suggesting a cumulative effect of light exposure. …”
Get full text
Article -
12
The Association of Retinal Disease with Vision Impairment and Functional Status in Medicare Patients
Published 2024-03-01“…**Background:** The association of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) with functional status in the general Medicare population are not well established. …”
Get full text
Article -
13
Multi-omic spatial effects on high-resolution AI-derived retinal thickness
Published 2025-02-01“…The macula is disproportionately affected by high disease burden retinal disorders such as age-related macular degeneration and diabetic retinopathy, which both involve metabolic dysregulation. …”
Get full text
Article -
14
Changes in Aqueous Humor Cytokine Profile Following Intravitreal Brolucizumab Injection
Published 2025-02-01“…Varis Ruamviboonsuk,1,2 Wijak Kongwattananon,1,3 Natthaya Chuaypen4 1Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 2Medical Science Program, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand; 4Metabolic Diseases in Gut and Urinary System Research Unit (MeDGURU), Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, ThailandCorrespondence: Wijak Kongwattananon, Center of Excellence in Retina, Department of Ophthalmology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathum Wan, Bangkok, 10330, Thailand, Tel +662 256 4000, Email wijak.k@chula.ac.thPurpose: Intravitreal brolucizumab, approved for neovascular age-related macular degeneration (nAMD), may trigger immune responses leading to intraocular inflammation (IOI) by increasing pro-inflammatory cytokines. …”
Get full text
Article -
15
From bench to bedside: Developing CRISPR/Cas-based therapy for ocular diseases
Published 2025-03-01“…To date, active trials include treatments for primary open angle glaucoma with MYOC mutations, refractory herpetic viral keratitis, CEP290-associated inherited retinal degenerations, neovascular age-related macular degeneration, and retinitis pigmentosa with RHO mutations. …”
Get full text
Article -
16
The effect of blue-blocking intraocular lenses on circadian biological rhythm: protocol for a randomised controlled trial (CLOCK-IOL colour study)
Published 2015-05-01“…Meanwhile, blue light causes photochemical damage to the retina, and may be associated with age-related macular degeneration (AMD). At present, clear intraocular lenses (IOLs) and blue-blocking IOLs are both widely used for cataract surgery; there is currently a lack of randomised controlled trials to determine whether clear or blue-blocking IOLs should be used.Methods and analysis This randomised controlled trial will recruit 1000 cataract patients and randomly allocate them to receive clear IOLs or blue-blocking IOLs in a ratio of 1:1. …”
Get full text
Article